Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
7 studies found for:    bapineuzumab | Phase 3
Show Display Options
RSS Create an RSS feed from your search for:
bapineuzumab | Phase 3
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Terminated
Has Results
A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease Patients
Condition: Alzheimer Disease
Interventions: Drug: Bapineuzumab 0.5 mg/kg;   Drug: Bapineuzumab 1.0 m/kg
2 Terminated Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
Condition: Alzheimer Disease
Interventions: Drug: bapineuzumab;   Drug: placebo
3 Terminated Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients
Condition: Alzheimer Disease
Interventions: Drug: bapineuzumab;   Drug: placebo
4 Completed Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier)
Condition: Alzheimer's Disease
Interventions: Drug: Bapineuzumab 0.5 mg/kg;   Drug: Placebo Control;   Drug: Bapineuzumab 1.0 m/kg
5 Completed Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)
Condition: Alzheimer's Disease
Interventions: Drug: Bapineuzumab 0.5 mg/kg;   Drug: Placebo Control;   Drug: Bapineuzumab 1.0 m/kg
6 Terminated A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients
Condition: Alzheimer Disease
Intervention: Drug: Bapineuzumab 0.5 mg/kg
7 Terminated A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Intervention: Drug: Bapineuzumab

Indicates status has not been verified in more than two years